Literature DB >> 25981904

Drug-induced movement disorders.

Dénes Zádori1, Gábor Veres, Levente Szalárdy, Péter Klivényi, László Vécsei.   

Abstract

INTRODUCTION: Drug-induced movement disorders (DIMDs) can be elicited by several kinds of pharmaceutical agents. The major groups of offending drugs include antidepressants, antipsychotics, antiepileptics, antimicrobials, antiarrhythmics, mood stabilisers and gastrointestinal drugs among others. AREAS COVERED: This paper reviews literature covering each movement disorder induced by commercially available pharmaceuticals. Considering the magnitude of the topic, only the most prominent examples of offending agents were reported in each paragraph paying a special attention to the brief description of the pathomechanism and therapeutic options if available. EXPERT OPINION: As the treatment of some DIMDs is quite challenging, a preventive approach is preferable. Accordingly, the use of the offending agents should be strictly limited to appropriate indications and they should be applied in as low doses and as short duration as the patient's condition allows. As most of DIMDs are related to an unspecific adverse action of medications in the basal ganglia and the cerebellum, future research should focus on better characterisation of the neurochemical profile of the affected functional systems, in addition to the development of drugs with higher selectivity and better side-effect profile.

Entities:  

Keywords:  basal ganglia; drug-induced side-effects; movement disorders; tardive syndromes

Mesh:

Year:  2015        PMID: 25981904     DOI: 10.1517/14740338.2015.1032244

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  9 in total

1.  L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza's syndrome.

Authors:  Upinder Kaur; Pritam Das; Indrajeet Singh Gambhir; Sankha Shubhra Chakrabarti
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

Review 2.  Blepharospasm 40 years later.

Authors:  Giovanni Defazio; Mark Hallett; Hyder A Jinnah; Antonella Conte; Alfredo Berardelli
Journal:  Mov Disord       Date:  2017-02-10       Impact factor: 10.338

Review 3.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

4.  Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia.

Authors:  Assefa Kumsa; Shimelis Girma; Bezaye Alemu; Liyew Agenagnew
Journal:  Clin Pharmacol       Date:  2020-12-01

5.  An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019.

Authors:  Prasad S Nishtala; Te-Yuan Chyou
Journal:  Drugs Aging       Date:  2022-07-13       Impact factor: 4.271

6.  Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic.

Authors:  Assefa Kumsa; Liyew Agenagnew; Beza Alemu; Shimelis Girma
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

7.  COVID-19 Associated Acute Necrotizing Encephalopathy Presenting as Parkinsonism and Myorhythmia.

Authors:  Tien Lee Ong; Khariah Mat Nor; Yusniza Yusoff; Sapiah Sapuan
Journal:  J Mov Disord       Date:  2021-11-17

Review 8.  Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.

Authors:  Robert A Hauser; Jonathan M Meyer; Stewart A Factor; Cynthia L Comella; Caroline M Tanner; Rose Mary Xavier; Stanley N Caroff; Leslie Lundt
Journal:  CNS Spectr       Date:  2020-11-20       Impact factor: 4.604

9.  Pediatric Anti-N-methyl-D-aspartate Receptor Encephalitis Mimicking Glutaric Aciduria Type 1: A Case Report.

Authors:  Daniel Almeida do Valle; Mara Lúcia Schmitz Ferreira Santos; Michelle Silva Zeny; Mara L Cordeiro
Journal:  Front Neurol       Date:  2020-10-26       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.